Company news
Fulgent Genetics, Inc. (NASDAQ:FLGT) news
Every Fulgent Genetics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Fulgent Reports Second Quarter 2026 Financial Results
July 30, 2026
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
July 9, 2026
Flagship Pioneering Announces Formation of Terion, a Company Delivering the Digital Infrastructure to Power Modern Agriculture
June 18, 2026
Fulgent Presents Updated FID-007 Data at ASCO 2026
June 1, 2026
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual ...
May 21, 2026
Fulgent Reports First Quarter 2026 Financial Results
May 1, 2026
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
April 22, 2026
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
April 16, 2026
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
March 17, 2026
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results
February 27, 2026
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
February 12, 2026
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
December 22, 2025
Fulgent Reports Third Quarter 2025 Financial Results
November 7, 2025
Fulgent to Participate in Upcoming Conferences
November 7, 2025
Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference
October 20, 2025
Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025
October 16, 2025
Fulgent Reports Second Quarter 2025 Financial Results
August 1, 2025
Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM
July 17, 2025
Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025
July 10, 2025
Fulgent Reports First Quarter 2025 Financial Results
May 2, 2025
Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025
April 10, 2025
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
February 28, 2025
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
February 6, 2025
Fulgent Reports Third Quarter 2024 Financial Results
November 8, 2024
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Gene...
October 31, 2024
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
October 17, 2024
Fulgent Reports Second Quarter 2024 Financial Results
August 2, 2024
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
July 11, 2024
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
June 3, 2024
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
May 24, 2024
Fulgent Reports First Quarter 2024 Financial Results
May 3, 2024
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
April 11, 2024
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
February 13, 2024
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
February 9, 2024
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
Fulgent Reports Third Quarter 2023 Financial Results
November 3, 2023
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
November 3, 2023
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
October 25, 2023
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
October 17, 2023
Fulgent Reports Second Quarter 2023 Financial Results
August 4, 2023
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
July 18, 2023
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
June 5, 2023
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
May 18, 2023
Fulgent Reports First Quarter 2023 Financial Results
May 5, 2023
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
April 20, 2023
Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
February 28, 2023
Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
Fulgent to Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
February 23, 2023
Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
February 14, 2023